Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions

Table 1 Primer sequences used for amplification of mRNA by semi-quantitative PCR

mRNA	Forward primer (5’-3’)	Reverse primer (5’-3’)	Size (bp)
PCNA	CTTTTCTGTCACCAAATTTGTACC	AACTGCATTTAGAGTCAAGACCC	206
Fas	CTGCCAAGAAGGGAAGGAGT	GGTGCAAGGGTCACAGTGTT	189
PPARγ	AGCCTCATGAAGAGCCTTCCA	ACCCTTGCATCCTTCACAAGC	89
β-actin	GTCTTCCCCTCCATCGTG	GGGTGAGGATGCCTCTCTT	251

Table 2 Effect of celecoxib on the histological improvement of gastric precancerous lesions

Precancerous lesions	Regression site n (%)		P-value
	Celecoxib group	Placebo group
Atrophy	11/13 (84.6)	7/13 (53.8)	0.202
Metaplasia	9/14 (64.3)	9/18 (50)	0.419
Atrophy + metaplasia1	3/4 (75)	3/6 (50)	0.895
Dysplasia	35/39 (89.7)	24/40 (60)	0.002

¹Indicates that both atrophy and metaplasia were regressed in one site.

Table 3 Effect of celecoxib on COX-2 expression and other parameters

	Celecoxib group n (%)			Placebo group n (%)
	Reduction	Same	Worse	Reduction	Same	Worse
COX-2 expression	22 (73)	4 (13)	4 (13)	15 (48)	3 (10)	13 (43)
Cell proliferation	23 (77)	2 (7)	5 (17)	11 (37)	3 (10)	16 (53)
Cell apoptosis	8 (53)	4 (27)	3 (20)	4 (27)	5 (17)	6 (40)
Angiogenesis	22 (73)	4 (13)	4 (13)	12 (39)	10 (32)	9 (29)
PPARγ expression	15 (50)	5 (17)	10 (33)	9 (29)	5 (16)	17 (55)